On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation ...

The FDA’s upcoming June meeting plans to jab at a lineup of vaccines—COVID-19, RSV, flu, and even anthrax—but somehow skipped ...

RFK Jr.’s newly appointed CDC vaccine panel will not review HPV or meningitis vaccines but will vote on thimerosal, a ...

A newly posted agenda for next week’s meeting of the just-appointed group of outside vaccine advisers to the US Centers for ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

aNational Institute for Health and Care Research Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, UK bFaculty of Medicine ...

Retifanlimab became the first FDA-approved frontline treatment for advanced anal cancer, providing new combination and monotherapy options. Jivi's indication was expanded to include pediatric ...

FDA commissioner Dr. Marty Makary shared a major outcome: “Today, we met our goal ahead of schedule and under budget,” he said. “What took one scientific reviewer two to three days [before] ...

There are currently three vaccines approved for RSV; two of them -- GSK's Arexvy and ... mResvia in the 18-to-59-year age group, and the FDA is expected to make a decision on that application ...

Maternal vaccination and nirsevimab were associated with estimated rate reductions in RSV-associated hospitalization among infants aged 0 to 7 months of 43% and 28%, respectively. HealthDay News — ...